Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …

Lung cancer causes significant morbidity and mortality in China and worldwide. In China,
lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer …

Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with
the development of targeted therapies for advanced disease and concomitant molecular …

Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …

Non‑small cell lung cancer (NSCLC) accounts for~ 85% of lung cancer cases and has high
morbidity and mortality rates. Over the past decade, treatment strategies for NSCLC have …

Importance Valuable evidence regarding clinical characteristics, treatments, and outcomes
for non–small cell lung cancer (NSCLC) is limited to individual hospital databases or …

Background The PACIFIC trial findings drastically changed the c-stage III non-small cell lung
cancer (NSCLC) treatment strategy. However, it remains uncertain whether surgery is no …

This multicentre, two-arm, phase 2 study aimed to explore the efficacy and safety of
neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially …

Background: We aimed to formulate and validate nomograms to unravel the significant risk
factors associated with lymph node metastasis (LNM) and distant metastasis in early-stage …

Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped
according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3 years have been …